Histopathology of osteoarthrosis of a knee joint in an elderly female. Credit: KGH.

Aevi Genomic Medicine has reported negative results from the Phase II AEVI-001-ADHD-202 (ASCEND) trial after it failed to meet the primary endpoint of the study.

The dose-optimisation, parallel-group study evaluated AEVI-001 in children aged six to 17 with attention deficit hyperactivity disorder (ADHD) with or without an mGluR copy number variant.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Primary endpoints of the trial included the reduction of ADHD-RS in the patients following six weeks of treatment with AEVI-001.

Results showed that AEVI-001 was safe and well tolerated with minimal adverse events reported among patients in both treatment groups.

Aevi Genomic Medicine CEO Michael Cola said: “We are very disappointed that the ASCEND trial did not achieve its primary endpoint.

“We plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options.”

“We plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will continue to focus on our pipeline of additional molecules, including AEVI-002 for severe pediatric-onset Crohn’s Disease and AEVI-005 for an undisclosed autoimmune orphan disease, both partnered with Kyowa Hakko Kirin.”

Aevi investigated orally-administered 100mg-400mg of AEVI-001 as part of the ASCEND trial.

The genomically-guided, double-blind, placebo-controlled study was conducted in two parts.

Part A of the trial included 69 subjects who have one of eight specific gene mutations implicated in glutamatergic signalling and neuronal connectivity.

Part B enrolled 109 subjects who did not have copy number variants (CNVs) in any of the specific gene mutations implicated in glutamatergic signalling and neuronal connectivity.

Both groups saw subjects randomised in 1:1 ratio to receive either AEVI-001 or placebo.

After being treated with the titrated dose of up to 400mg of AEVI-001, the participants entered a maintenance phase with weekly follow-up for up to six weeks.